PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer

Qiuming He; Zheyu Ding; Tingna Chen; Haitao Wu; Jialing Song; Zhenxian Xiang; Chaogang Yang; Shuyi Wang; Bin Xiong

doi:10.3389/fonc.2023.1164070

PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer

Front Oncol. 2023 Jul 18:13:1164070. doi: 10.3389/fonc.2023.1164070. eCollection 2023.

Authors

Qiuming He^{1

2

3}, Zheyu Ding^{1

3}, Tingna Chen^{1

3}, Haitao Wu⁴, Jialing Song^{1

3}, Zhenxian Xiang^{1

3}, Chaogang Yang^{1

3}, Shuyi Wang^{1

3}, Bin Xiong^{1

3}

Affiliations

¹ Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
² Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³ Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.
⁴ Department of Thyroid and Breast Surgery, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

Gastric cancer (GC) is a major health burden worldwide, but our understanding of GC is limited, and the prognosis is poor. Novel therapeutic strategies and biomarkers are urgently needed to improve GC patient outcomes. Previously, we identified PFDN2 as a novel key gene in gastric cancer based on its differential expression between cancer and normal tissues. However, the role and underlying mechanisms of PFDN2 in GC remain elusive. In this article, we demonstrated that PFDN2 is highly expressed in GC and that upregulation of PFDN2 is associated with the progression of GC. We further found that PFDN2 could promote cell cycle progression by promoting MYBL2 expression. Mechanistically, we demonstrated that PFDN2 could upregulate MYBL2 expression by facilitating the nuclear translocation of hnRNPD, and thus promoting MYBL2 transcriptional program. In conclusion, we found that PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis and may serve as a potential biomarker and therapeutic target for GC.

Keywords: Cell Cycle; HNRNPD; MYBL2; PFDN2; gastric cancer.

Grants and funding

This work was supported by grants from the Health Commission of Hubei Province Scientific Research Project (No. WJ2019H012), Improvement Project for Theragnostic ability on Difficulty miscellaneous disease (Tumor) (No. ZLYNXM202018), National Key Clinical Specialty Construction Project and National Natural Science Fund Youth Fund of China (No. 81702411).